MLM
TCRT icon

Mount Lucas Management’s Alaunos Therapeutics TCRT Stock Holding History

Mount Lucas Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-43
Closed -$40K – 143
2017
Q2 		$40K Buy
+43
New +$42.2K 0.01% 141
2016
Q4 		– Sell
-43
Closed -$37K – 167
2016
Q3 		$37K Buy
43
+3
+8% +$2.41K 0.01% 149
2016
Q2 		$33K Hold
40
– – 0.01% 136
2016
Q1 		$45K Buy
+40
New +$40.9K 0.01% 105

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mount Lucas Management's TCRT Position: Q3 2017 in Review

Mount Lucas Management sold out of Alaunos Therapeutics (TCRT) in Q3 2017, closing a stake of 43 shares — an estimated $40K sold.

Mount Lucas Management first reported a position in TCRT in Q1 2016 and held it in 4 quarters. The position peaked at $45K in Q1 2016. 122 funds tracked by Wall St. Rank hold TCRT as of Q3 2017.

  • Mount Lucas Management reported no remaining Alaunos Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Mount Lucas Management sold 43 Alaunos Therapeutics shares in Q3 2017, an estimated $40K.
  • Mount Lucas Management first reported a position in Alaunos Therapeutics in Q1 2016 and held it in 4 quarters.
  • Mount Lucas Management's Alaunos Therapeutics position peaked at $45K in Q1 2016.
  • 122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2017.

Based on Mount Lucas Management's 13F filing for Q3 2017, filed 14 Nov 2017.